Research and Development
Resonance Health has an active R&D program that includes current research in the following areas:
Liver Fibrosis & Inflammation
The software tool under development is an MRI based non-invasive biomarker for quantifying liver fibrosis and inflammation without additional equipment and contrast agent.
Resonance Health has conducted a proof-of-concept (PoC) study to develop predictive model(s) of liver fibrosis and inflammation based on proprietary MRI data analysis methods using liver biopsy as the reference standard. Initial results are promising and we are commencing an expanded PoC study targeting more balanced fibrosis gradings for further improvement of statistical power. Following the expanded PoC, we will conduct a validation study and seek regulatory clearances in key markets.
Cardiac T2* 1.5T to 3T Calibration
With the successful expansion of FerriScan 3T, there is a demand for the availability of Cardiac T2* for 3T as a paired service with FerriScan 3T for both clinical trials as well as clinical/commercial practice.
FerriScan Shorter Acquisition (SA) Development
FerriScan currently takes about 9 minutes to complete the required 5 separate sequences. The new protocol aims to shorten this time to 1.5 -2 minutes.
Other projects in development include:
- AI development for existing products and new ones, such as, CardiacT2*, organ volumetric quantification, radiology assistant tools and others
- Liver R2* Development
- Other organs of interest
